Physician profile
Maxwell Matson
NPI 1669867719
$426.66
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $372 · 2020: $23.33 · 2022: $31.64.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $73.28 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.22 | 2019-2020 | |
| Novo Nordisk INC | $55.41 | 2019 | |
| Lilly USA, LLC | $47.01 | 2019-2022 | |
| Pfizer INC. | $39.65 | 2019 | |
| Amgen INC. | $37.41 | 2019 | |
| Janssen Pharmaceuticals, INC | $28.75 | 2019 | |
| Amarin Pharma, INC. | $16.22 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.41 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.10 | 2019 | |
| Merck Sharp & Dohme LLC | $11.65 | 2019 | |
| Glaxosmithkline, LLC. | $11.41 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.14 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maxwell Matson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.